nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—migraine—Prednisone—hematologic cancer	0.413	1	CpDpCtD
Ergotamine—ABCB1—hematologic cancer	0.0547	1	CbGaD
Ergotamine—CYP1A2—Anagrelide—hematologic cancer	0.0254	0.0753	CbGbCtD
Ergotamine—ABCB1—Lenalidomide—hematologic cancer	0.0154	0.0456	CbGbCtD
Ergotamine—CYP1A2—Carmustine—hematologic cancer	0.0134	0.0395	CbGbCtD
Ergotamine—CYP1A2—Methoxsalen—hematologic cancer	0.0114	0.0336	CbGbCtD
Ergotamine—CYP1A2—Bortezomib—hematologic cancer	0.0108	0.032	CbGbCtD
Ergotamine—CYP1A2—Daunorubicin—hematologic cancer	0.0103	0.0306	CbGbCtD
Ergotamine—CYP1A2—Alitretinoin—hematologic cancer	0.0101	0.03	CbGbCtD
Ergotamine—CYP1A2—Thalidomide—hematologic cancer	0.00941	0.0279	CbGbCtD
Ergotamine—CYP3A4—Bexarotene—hematologic cancer	0.00923	0.0273	CbGbCtD
Ergotamine—ABCB1—Daunorubicin—hematologic cancer	0.00903	0.0267	CbGbCtD
Ergotamine—ABCB1—Alitretinoin—hematologic cancer	0.00885	0.0262	CbGbCtD
Ergotamine—CYP3A4—Lomustine—hematologic cancer	0.00858	0.0254	CbGbCtD
Ergotamine—CYP3A4—Busulfan—hematologic cancer	0.00858	0.0254	CbGbCtD
Ergotamine—CYP1A2—Dacarbazine—hematologic cancer	0.00809	0.0239	CbGbCtD
Ergotamine—CYP1A2—Imatinib—hematologic cancer	0.00791	0.0234	CbGbCtD
Ergotamine—CYP3A4—Thiotepa—hematologic cancer	0.00765	0.0226	CbGbCtD
Ergotamine—ABCB1—Imatinib—hematologic cancer	0.00692	0.0205	CbGbCtD
Ergotamine—CYP1A2—Dasatinib—hematologic cancer	0.00635	0.0188	CbGbCtD
Ergotamine—ABCB1—Nilotinib—hematologic cancer	0.00629	0.0186	CbGbCtD
Ergotamine—ABCB1—Vinorelbine—hematologic cancer	0.00623	0.0185	CbGbCtD
Ergotamine—CYP3A4—Methoxsalen—hematologic cancer	0.00595	0.0176	CbGbCtD
Ergotamine—CYP3A4—Bortezomib—hematologic cancer	0.00566	0.0167	CbGbCtD
Ergotamine—ABCB1—Dasatinib—hematologic cancer	0.00556	0.0165	CbGbCtD
Ergotamine—ABCB1—Mitoxantrone—hematologic cancer	0.00549	0.0162	CbGbCtD
Ergotamine—CYP3A4—Daunorubicin—hematologic cancer	0.00541	0.016	CbGbCtD
Ergotamine—ABCB1—Betamethasone—hematologic cancer	0.00489	0.0145	CbGbCtD
Ergotamine—ABCB1—Gemcitabine—hematologic cancer	0.00485	0.0144	CbGbCtD
Ergotamine—ABCB1—Prednisolone—hematologic cancer	0.00483	0.0143	CbGbCtD
Ergotamine—CYP3A4—Cytarabine—hematologic cancer	0.00477	0.0141	CbGbCtD
Ergotamine—CYP3A4—Teniposide—hematologic cancer	0.0047	0.0139	CbGbCtD
Ergotamine—ABCB1—Prednisone—hematologic cancer	0.00456	0.0135	CbGbCtD
Ergotamine—CYP3A4—Ifosfamide—hematologic cancer	0.00434	0.0128	CbGbCtD
Ergotamine—ABCB1—Irinotecan—hematologic cancer	0.00432	0.0128	CbGbCtD
Ergotamine—CYP3A4—Imatinib—hematologic cancer	0.00415	0.0123	CbGbCtD
Ergotamine—CYP1A2—Etoposide—hematologic cancer	0.00396	0.0117	CbGbCtD
Ergotamine—CYP3A4—Ruxolitinib—hematologic cancer	0.0039	0.0116	CbGbCtD
Ergotamine—ABCB1—Vinblastine—hematologic cancer	0.00384	0.0114	CbGbCtD
Ergotamine—ABCB1—Vincristine—hematologic cancer	0.00378	0.0112	CbGbCtD
Ergotamine—CYP3A4—Nilotinib—hematologic cancer	0.00377	0.0112	CbGbCtD
Ergotamine—CYP3A4—Vinorelbine—hematologic cancer	0.00374	0.0111	CbGbCtD
Ergotamine—ABCB1—Cisplatin—hematologic cancer	0.00352	0.0104	CbGbCtD
Ergotamine—ABCB1—Etoposide—hematologic cancer	0.00346	0.0102	CbGbCtD
Ergotamine—CYP3A4—Triamcinolone—hematologic cancer	0.00342	0.0101	CbGbCtD
Ergotamine—CYP3A4—Dasatinib—hematologic cancer	0.00333	0.00986	CbGbCtD
Ergotamine—CYP3A4—Mitoxantrone—hematologic cancer	0.00329	0.00974	CbGbCtD
Ergotamine—CYP3A4—Betamethasone—hematologic cancer	0.00293	0.00868	CbGbCtD
Ergotamine—CYP3A4—Prednisolone—hematologic cancer	0.00289	0.00856	CbGbCtD
Ergotamine—ABCB1—Dexamethasone—hematologic cancer	0.00285	0.00842	CbGbCtD
Ergotamine—CYP3A4—Prednisone—hematologic cancer	0.00273	0.00809	CbGbCtD
Ergotamine—CYP3A4—Irinotecan—hematologic cancer	0.00259	0.00767	CbGbCtD
Ergotamine—ABCB1—Doxorubicin—hematologic cancer	0.00236	0.00699	CbGbCtD
Ergotamine—CYP3A4—Vinblastine—hematologic cancer	0.0023	0.00681	CbGbCtD
Ergotamine—ABCB1—Methotrexate—hematologic cancer	0.00229	0.00677	CbGbCtD
Ergotamine—CYP3A4—Vincristine—hematologic cancer	0.00226	0.0067	CbGbCtD
Ergotamine—CYP3A4—Etoposide—hematologic cancer	0.00207	0.00614	CbGbCtD
Ergotamine—CYP3A4—Dexamethasone—hematologic cancer	0.00171	0.00505	CbGbCtD
Ergotamine—CYP3A4—Doxorubicin—hematologic cancer	0.00141	0.00419	CbGbCtD
Ergotamine—Nausea—Idarubicin—hematologic cancer	0.000168	0.00145	CcSEcCtD
Ergotamine—Hypoaesthesia—Etoposide—hematologic cancer	0.000168	0.00144	CcSEcCtD
Ergotamine—Vertigo—Ifosfamide—hematologic cancer	0.000167	0.00144	CcSEcCtD
Ergotamine—Pain—Lenalidomide—hematologic cancer	0.000166	0.00143	CcSEcCtD
Ergotamine—Asthenia—Chlorambucil—hematologic cancer	0.000164	0.00141	CcSEcCtD
Ergotamine—Hypertension—Carmustine—hematologic cancer	0.000164	0.00141	CcSEcCtD
Ergotamine—Pain—Hydroxyurea—hematologic cancer	0.000164	0.00141	CcSEcCtD
Ergotamine—Nausea—Teniposide—hematologic cancer	0.000163	0.00141	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Bortezomib—hematologic cancer	0.000163	0.0014	CcSEcCtD
Ergotamine—Vertigo—Vincristine—hematologic cancer	0.000163	0.0014	CcSEcCtD
Ergotamine—Tachycardia—Thiotepa—hematologic cancer	0.000163	0.0014	CcSEcCtD
Ergotamine—Hypertension—Alitretinoin—hematologic cancer	0.000162	0.0014	CcSEcCtD
Ergotamine—Vomiting—Busulfan—hematologic cancer	0.000162	0.0014	CcSEcCtD
Ergotamine—Pruritus—Chlorambucil—hematologic cancer	0.000162	0.00139	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Bleomycin—hematologic cancer	0.000161	0.00139	CcSEcCtD
Ergotamine—Myalgia—Carmustine—hematologic cancer	0.000161	0.00139	CcSEcCtD
Ergotamine—Asthenia—Nilotinib—hematologic cancer	0.000161	0.00138	CcSEcCtD
Ergotamine—Paraesthesia—Bortezomib—hematologic cancer	0.00016	0.00138	CcSEcCtD
Ergotamine—Hypertension—Ifosfamide—hematologic cancer	0.00016	0.00138	CcSEcCtD
Ergotamine—Myalgia—Alitretinoin—hematologic cancer	0.00016	0.00138	CcSEcCtD
Ergotamine—Asthenia—Imatinib—hematologic cancer	0.00016	0.00138	CcSEcCtD
Ergotamine—Paraesthesia—Bleomycin—hematologic cancer	0.000159	0.00137	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Vinorelbine—hematologic cancer	0.000159	0.00137	CcSEcCtD
Ergotamine—Pruritus—Nilotinib—hematologic cancer	0.000158	0.00136	CcSEcCtD
Ergotamine—Vertigo—Irinotecan—hematologic cancer	0.000158	0.00136	CcSEcCtD
Ergotamine—Myalgia—Ifosfamide—hematologic cancer	0.000158	0.00136	CcSEcCtD
Ergotamine—Pruritus—Imatinib—hematologic cancer	0.000158	0.00136	CcSEcCtD
Ergotamine—Vomiting—Procarbazine—hematologic cancer	0.000157	0.00135	CcSEcCtD
Ergotamine—Tachycardia—Thalidomide—hematologic cancer	0.000157	0.00135	CcSEcCtD
Ergotamine—Asthenia—Cladribine—hematologic cancer	0.000157	0.00135	CcSEcCtD
Ergotamine—Paraesthesia—Vinorelbine—hematologic cancer	0.000157	0.00135	CcSEcCtD
Ergotamine—Hypertension—Vincristine—hematologic cancer	0.000156	0.00134	CcSEcCtD
Ergotamine—Bradycardia—Triamcinolone—hematologic cancer	0.000155	0.00134	CcSEcCtD
Ergotamine—Pruritus—Cladribine—hematologic cancer	0.000155	0.00133	CcSEcCtD
Ergotamine—Vomiting—Bexarotene—hematologic cancer	0.000154	0.00133	CcSEcCtD
Ergotamine—Vomiting—Dasatinib—hematologic cancer	0.000154	0.00133	CcSEcCtD
Ergotamine—Myalgia—Vincristine—hematologic cancer	0.000154	0.00133	CcSEcCtD
Ergotamine—Vomiting—Fludarabine—hematologic cancer	0.000154	0.00132	CcSEcCtD
Ergotamine—Pain—Bortezomib—hematologic cancer	0.000153	0.00131	CcSEcCtD
Ergotamine—Hypertension—Irinotecan—hematologic cancer	0.000152	0.00131	CcSEcCtD
Ergotamine—Hypertension—Mitoxantrone—hematologic cancer	0.000152	0.00131	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Thiotepa—hematologic cancer	0.000152	0.00131	CcSEcCtD
Ergotamine—Pain—Bleomycin—hematologic cancer	0.000152	0.0013	CcSEcCtD
Ergotamine—Nausea—Busulfan—hematologic cancer	0.000151	0.0013	CcSEcCtD
Ergotamine—Tachycardia—Carmustine—hematologic cancer	0.000151	0.0013	CcSEcCtD
Ergotamine—Asthenia—Vinblastine—hematologic cancer	0.000151	0.0013	CcSEcCtD
Ergotamine—Myalgia—Mitoxantrone—hematologic cancer	0.00015	0.00129	CcSEcCtD
Ergotamine—Tachycardia—Alitretinoin—hematologic cancer	0.00015	0.00129	CcSEcCtD
Ergotamine—Paraesthesia—Thiotepa—hematologic cancer	0.00015	0.00129	CcSEcCtD
Ergotamine—Pain—Vinorelbine—hematologic cancer	0.000149	0.00128	CcSEcCtD
Ergotamine—Hypertension—Gemcitabine—hematologic cancer	0.000148	0.00128	CcSEcCtD
Ergotamine—Nausea—Procarbazine—hematologic cancer	0.000147	0.00126	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Thalidomide—hematologic cancer	0.000147	0.00126	CcSEcCtD
Ergotamine—Myalgia—Gemcitabine—hematologic cancer	0.000146	0.00126	CcSEcCtD
Ergotamine—Vomiting—Chlorambucil—hematologic cancer	0.000146	0.00125	CcSEcCtD
Ergotamine—Paraesthesia—Thalidomide—hematologic cancer	0.000145	0.00125	CcSEcCtD
Ergotamine—Nausea—Dasatinib—hematologic cancer	0.000144	0.00124	CcSEcCtD
Ergotamine—Nausea—Bexarotene—hematologic cancer	0.000144	0.00124	CcSEcCtD
Ergotamine—Nausea—Fludarabine—hematologic cancer	0.000144	0.00124	CcSEcCtD
Ergotamine—Asthenia—Melphalan—hematologic cancer	0.000143	0.00123	CcSEcCtD
Ergotamine—Pain—Thiotepa—hematologic cancer	0.000142	0.00123	CcSEcCtD
Ergotamine—Vomiting—Nilotinib—hematologic cancer	0.000142	0.00123	CcSEcCtD
Ergotamine—Vomiting—Imatinib—hematologic cancer	0.000142	0.00122	CcSEcCtD
Ergotamine—Pruritus—Melphalan—hematologic cancer	0.000141	0.00122	CcSEcCtD
Ergotamine—Bradycardia—Betamethasone—hematologic cancer	0.000141	0.00121	CcSEcCtD
Ergotamine—Bradycardia—Dexamethasone—hematologic cancer	0.000141	0.00121	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Carmustine—hematologic cancer	0.000141	0.00121	CcSEcCtD
Ergotamine—Tachycardia—Mitoxantrone—hematologic cancer	0.00014	0.00121	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Alitretinoin—hematologic cancer	0.00014	0.0012	CcSEcCtD
Ergotamine—Asthenia—Lenalidomide—hematologic cancer	0.000139	0.0012	CcSEcCtD
Ergotamine—Vomiting—Cladribine—hematologic cancer	0.000139	0.0012	CcSEcCtD
Ergotamine—Paraesthesia—Carmustine—hematologic cancer	0.000139	0.0012	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Ifosfamide—hematologic cancer	0.000138	0.00119	CcSEcCtD
Ergotamine—Pain—Thalidomide—hematologic cancer	0.000138	0.00119	CcSEcCtD
Ergotamine—Paraesthesia—Alitretinoin—hematologic cancer	0.000138	0.00118	CcSEcCtD
Ergotamine—Pruritus—Lenalidomide—hematologic cancer	0.000137	0.00118	CcSEcCtD
Ergotamine—Asthenia—Hydroxyurea—hematologic cancer	0.000137	0.00118	CcSEcCtD
Ergotamine—Myalgia—Cisplatin—hematologic cancer	0.000136	0.00117	CcSEcCtD
Ergotamine—Nausea—Chlorambucil—hematologic cancer	0.000136	0.00117	CcSEcCtD
Ergotamine—Paraesthesia—Ifosfamide—hematologic cancer	0.000136	0.00117	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Vincristine—hematologic cancer	0.000135	0.00116	CcSEcCtD
Ergotamine—Vomiting—Vinblastine—hematologic cancer	0.000133	0.00115	CcSEcCtD
Ergotamine—Nausea—Nilotinib—hematologic cancer	0.000133	0.00115	CcSEcCtD
Ergotamine—Paraesthesia—Vincristine—hematologic cancer	0.000133	0.00114	CcSEcCtD
Ergotamine—Pain—Carmustine—hematologic cancer	0.000132	0.00114	CcSEcCtD
Ergotamine—Nausea—Imatinib—hematologic cancer	0.000132	0.00114	CcSEcCtD
Ergotamine—Vertigo—Etoposide—hematologic cancer	0.000132	0.00113	CcSEcCtD
Ergotamine—Pain—Alitretinoin—hematologic cancer	0.000131	0.00113	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Mitoxantrone—hematologic cancer	0.000131	0.00113	CcSEcCtD
Ergotamine—Nausea—Cladribine—hematologic cancer	0.00013	0.00112	CcSEcCtD
Ergotamine—Vertigo—Prednisolone—hematologic cancer	0.00013	0.00112	CcSEcCtD
Ergotamine—Pain—Ifosfamide—hematologic cancer	0.00013	0.00112	CcSEcCtD
Ergotamine—Paraesthesia—Mitoxantrone—hematologic cancer	0.000129	0.00111	CcSEcCtD
Ergotamine—Paraesthesia—Irinotecan—hematologic cancer	0.000129	0.00111	CcSEcCtD
Ergotamine—Asthenia—Bortezomib—hematologic cancer	0.000128	0.0011	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Gemcitabine—hematologic cancer	0.000128	0.0011	CcSEcCtD
Ergotamine—Tachycardia—Cisplatin—hematologic cancer	0.000127	0.0011	CcSEcCtD
Ergotamine—Asthenia—Bleomycin—hematologic cancer	0.000127	0.00109	CcSEcCtD
Ergotamine—Vomiting—Melphalan—hematologic cancer	0.000127	0.00109	CcSEcCtD
Ergotamine—Hypertension—Etoposide—hematologic cancer	0.000127	0.00109	CcSEcCtD
Ergotamine—Pruritus—Bortezomib—hematologic cancer	0.000126	0.00109	CcSEcCtD
Ergotamine—Pain—Vincristine—hematologic cancer	0.000126	0.00109	CcSEcCtD
Ergotamine—Paraesthesia—Gemcitabine—hematologic cancer	0.000126	0.00108	CcSEcCtD
Ergotamine—Pruritus—Bleomycin—hematologic cancer	0.000125	0.00108	CcSEcCtD
Ergotamine—Asthenia—Vinorelbine—hematologic cancer	0.000125	0.00108	CcSEcCtD
Ergotamine—Hypertension—Prednisolone—hematologic cancer	0.000125	0.00107	CcSEcCtD
Ergotamine—Nausea—Vinblastine—hematologic cancer	0.000125	0.00107	CcSEcCtD
Ergotamine—Vomiting—Lenalidomide—hematologic cancer	0.000123	0.00106	CcSEcCtD
Ergotamine—Pruritus—Vinorelbine—hematologic cancer	0.000123	0.00106	CcSEcCtD
Ergotamine—Pain—Mitoxantrone—hematologic cancer	0.000123	0.00106	CcSEcCtD
Ergotamine—Pain—Irinotecan—hematologic cancer	0.000123	0.00106	CcSEcCtD
Ergotamine—Bradycardia—Prednisone—hematologic cancer	0.000123	0.00106	CcSEcCtD
Ergotamine—Vomiting—Hydroxyurea—hematologic cancer	0.000122	0.00105	CcSEcCtD
Ergotamine—Pain—Gemcitabine—hematologic cancer	0.00012	0.00103	CcSEcCtD
Ergotamine—Asthenia—Thiotepa—hematologic cancer	0.000119	0.00103	CcSEcCtD
Ergotamine—Vertigo—Triamcinolone—hematologic cancer	0.000119	0.00103	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Cisplatin—hematologic cancer	0.000119	0.00102	CcSEcCtD
Ergotamine—Nausea—Melphalan—hematologic cancer	0.000119	0.00102	CcSEcCtD
Ergotamine—Pruritus—Thiotepa—hematologic cancer	0.000118	0.00101	CcSEcCtD
Ergotamine—Paraesthesia—Cisplatin—hematologic cancer	0.000117	0.00101	CcSEcCtD
Ergotamine—Tachycardia—Etoposide—hematologic cancer	0.000117	0.00101	CcSEcCtD
Ergotamine—Asthenia—Thalidomide—hematologic cancer	0.000116	0.000995	CcSEcCtD
Ergotamine—Nausea—Lenalidomide—hematologic cancer	0.000115	0.000992	CcSEcCtD
Ergotamine—Tachycardia—Prednisolone—hematologic cancer	0.000115	0.000991	CcSEcCtD
Ergotamine—Hypertension—Triamcinolone—hematologic cancer	0.000115	0.000988	CcSEcCtD
Ergotamine—Pruritus—Thalidomide—hematologic cancer	0.000114	0.000981	CcSEcCtD
Ergotamine—Nausea—Hydroxyurea—hematologic cancer	0.000114	0.000979	CcSEcCtD
Ergotamine—Vomiting—Bortezomib—hematologic cancer	0.000114	0.000978	CcSEcCtD
Ergotamine—Myalgia—Triamcinolone—hematologic cancer	0.000113	0.000974	CcSEcCtD
Ergotamine—Vomiting—Bleomycin—hematologic cancer	0.000113	0.00097	CcSEcCtD
Ergotamine—Pain—Cisplatin—hematologic cancer	0.000112	0.000961	CcSEcCtD
Ergotamine—Asthenia—Carmustine—hematologic cancer	0.000111	0.000955	CcSEcCtD
Ergotamine—Vomiting—Vinorelbine—hematologic cancer	0.000111	0.000954	CcSEcCtD
Ergotamine—Asthenia—Alitretinoin—hematologic cancer	0.00011	0.000947	CcSEcCtD
Ergotamine—Asthenia—Ifosfamide—hematologic cancer	0.000109	0.000935	CcSEcCtD
Ergotamine—Pruritus—Alitretinoin—hematologic cancer	0.000108	0.000933	CcSEcCtD
Ergotamine—Vertigo—Betamethasone—hematologic cancer	0.000108	0.000933	CcSEcCtD
Ergotamine—Vertigo—Dexamethasone—hematologic cancer	0.000108	0.000933	CcSEcCtD
Ergotamine—Paraesthesia—Etoposide—hematologic cancer	0.000107	0.000925	CcSEcCtD
Ergotamine—Pruritus—Ifosfamide—hematologic cancer	0.000107	0.000922	CcSEcCtD
Ergotamine—Nausea—Bortezomib—hematologic cancer	0.000106	0.000913	CcSEcCtD
Ergotamine—Asthenia—Vincristine—hematologic cancer	0.000106	0.000912	CcSEcCtD
Ergotamine—Paraesthesia—Prednisolone—hematologic cancer	0.000106	0.000912	CcSEcCtD
Ergotamine—Tachycardia—Triamcinolone—hematologic cancer	0.000106	0.000912	CcSEcCtD
Ergotamine—Vomiting—Thiotepa—hematologic cancer	0.000106	0.000912	CcSEcCtD
Ergotamine—Nausea—Bleomycin—hematologic cancer	0.000105	0.000906	CcSEcCtD
Ergotamine—Hypertension—Dexamethasone—hematologic cancer	0.000104	0.000897	CcSEcCtD
Ergotamine—Hypertension—Betamethasone—hematologic cancer	0.000104	0.000897	CcSEcCtD
Ergotamine—Nausea—Vinorelbine—hematologic cancer	0.000104	0.000892	CcSEcCtD
Ergotamine—Asthenia—Mitoxantrone—hematologic cancer	0.000103	0.000888	CcSEcCtD
Ergotamine—Asthenia—Irinotecan—hematologic cancer	0.000103	0.000888	CcSEcCtD
Ergotamine—Myalgia—Betamethasone—hematologic cancer	0.000103	0.000884	CcSEcCtD
Ergotamine—Myalgia—Dexamethasone—hematologic cancer	0.000103	0.000884	CcSEcCtD
Ergotamine—Vomiting—Thalidomide—hematologic cancer	0.000102	0.000882	CcSEcCtD
Ergotamine—Pain—Etoposide—hematologic cancer	0.000102	0.000881	CcSEcCtD
Ergotamine—Pain—Prednisolone—hematologic cancer	0.000101	0.000869	CcSEcCtD
Ergotamine—Asthenia—Gemcitabine—hematologic cancer	0.000101	0.000865	CcSEcCtD
Ergotamine—Pruritus—Gemcitabine—hematologic cancer	9.91e-05	0.000853	CcSEcCtD
Ergotamine—Nausea—Thiotepa—hematologic cancer	9.89e-05	0.000852	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	9.89e-05	0.000851	CcSEcCtD
Ergotamine—Vomiting—Carmustine—hematologic cancer	9.84e-05	0.000847	CcSEcCtD
Ergotamine—Vomiting—Alitretinoin—hematologic cancer	9.74e-05	0.000839	CcSEcCtD
Ergotamine—Paraesthesia—Triamcinolone—hematologic cancer	9.74e-05	0.000839	CcSEcCtD
Ergotamine—Vomiting—Ifosfamide—hematologic cancer	9.63e-05	0.000829	CcSEcCtD
Ergotamine—Tachycardia—Dexamethasone—hematologic cancer	9.61e-05	0.000827	CcSEcCtD
Ergotamine—Tachycardia—Betamethasone—hematologic cancer	9.61e-05	0.000827	CcSEcCtD
Ergotamine—Bradycardia—Epirubicin—hematologic cancer	9.61e-05	0.000827	CcSEcCtD
Ergotamine—Nausea—Thalidomide—hematologic cancer	9.57e-05	0.000824	CcSEcCtD
Ergotamine—Vertigo—Prednisone—hematologic cancer	9.44e-05	0.000813	CcSEcCtD
Ergotamine—Hypoaesthesia—Epirubicin—hematologic cancer	9.39e-05	0.000808	CcSEcCtD
Ergotamine—Vomiting—Vincristine—hematologic cancer	9.39e-05	0.000808	CcSEcCtD
Ergotamine—Asthenia—Cisplatin—hematologic cancer	9.37e-05	0.000807	CcSEcCtD
Ergotamine—Pain—Triamcinolone—hematologic cancer	9.28e-05	0.000799	CcSEcCtD
Ergotamine—Nausea—Carmustine—hematologic cancer	9.19e-05	0.000791	CcSEcCtD
Ergotamine—Vomiting—Irinotecan—hematologic cancer	9.14e-05	0.000787	CcSEcCtD
Ergotamine—Vomiting—Mitoxantrone—hematologic cancer	9.14e-05	0.000787	CcSEcCtD
Ergotamine—Nausea—Alitretinoin—hematologic cancer	9.1e-05	0.000784	CcSEcCtD
Ergotamine—Hypertension—Prednisone—hematologic cancer	9.07e-05	0.000781	CcSEcCtD
Ergotamine—Nausea—Ifosfamide—hematologic cancer	9e-05	0.000774	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	8.97e-05	0.000772	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	8.97e-05	0.000772	CcSEcCtD
Ergotamine—Myalgia—Prednisone—hematologic cancer	8.94e-05	0.00077	CcSEcCtD
Ergotamine—Vomiting—Gemcitabine—hematologic cancer	8.91e-05	0.000767	CcSEcCtD
Ergotamine—Bradycardia—Doxorubicin—hematologic cancer	8.89e-05	0.000765	CcSEcCtD
Ergotamine—Paraesthesia—Betamethasone—hematologic cancer	8.84e-05	0.000761	CcSEcCtD
Ergotamine—Paraesthesia—Dexamethasone—hematologic cancer	8.84e-05	0.000761	CcSEcCtD
Ergotamine—Nausea—Vincristine—hematologic cancer	8.77e-05	0.000755	CcSEcCtD
Ergotamine—Hypoaesthesia—Doxorubicin—hematologic cancer	8.69e-05	0.000748	CcSEcCtD
Ergotamine—Asthenia—Etoposide—hematologic cancer	8.58e-05	0.000739	CcSEcCtD
Ergotamine—Nausea—Irinotecan—hematologic cancer	8.54e-05	0.000735	CcSEcCtD
Ergotamine—Nausea—Mitoxantrone—hematologic cancer	8.54e-05	0.000735	CcSEcCtD
Ergotamine—Pruritus—Etoposide—hematologic cancer	8.46e-05	0.000729	CcSEcCtD
Ergotamine—Pain—Dexamethasone—hematologic cancer	8.42e-05	0.000725	CcSEcCtD
Ergotamine—Pain—Betamethasone—hematologic cancer	8.42e-05	0.000725	CcSEcCtD
Ergotamine—Tachycardia—Prednisone—hematologic cancer	8.37e-05	0.00072	CcSEcCtD
Ergotamine—Nausea—Gemcitabine—hematologic cancer	8.32e-05	0.000716	CcSEcCtD
Ergotamine—Vomiting—Cisplatin—hematologic cancer	8.3e-05	0.000715	CcSEcCtD
Ergotamine—Vertigo—Methotrexate—hematologic cancer	7.89e-05	0.000679	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Prednisone—hematologic cancer	7.81e-05	0.000672	CcSEcCtD
Ergotamine—Asthenia—Triamcinolone—hematologic cancer	7.78e-05	0.00067	CcSEcCtD
Ergotamine—Nausea—Cisplatin—hematologic cancer	7.76e-05	0.000668	CcSEcCtD
Ergotamine—Paraesthesia—Prednisone—hematologic cancer	7.7e-05	0.000663	CcSEcCtD
Ergotamine—Pruritus—Triamcinolone—hematologic cancer	7.68e-05	0.000661	CcSEcCtD
Ergotamine—Vomiting—Etoposide—hematologic cancer	7.61e-05	0.000655	CcSEcCtD
Ergotamine—Myalgia—Methotrexate—hematologic cancer	7.47e-05	0.000643	CcSEcCtD
Ergotamine—Vertigo—Epirubicin—hematologic cancer	7.38e-05	0.000635	CcSEcCtD
Ergotamine—Nausea—Etoposide—hematologic cancer	7.11e-05	0.000612	CcSEcCtD
Ergotamine—Hypertension—Epirubicin—hematologic cancer	7.09e-05	0.000611	CcSEcCtD
Ergotamine—Asthenia—Dexamethasone—hematologic cancer	7.06e-05	0.000608	CcSEcCtD
Ergotamine—Asthenia—Betamethasone—hematologic cancer	7.06e-05	0.000608	CcSEcCtD
Ergotamine—Nausea—Prednisolone—hematologic cancer	7.01e-05	0.000603	CcSEcCtD
Ergotamine—Myalgia—Epirubicin—hematologic cancer	7e-05	0.000602	CcSEcCtD
Ergotamine—Pruritus—Betamethasone—hematologic cancer	6.97e-05	0.0006	CcSEcCtD
Ergotamine—Pruritus—Dexamethasone—hematologic cancer	6.97e-05	0.0006	CcSEcCtD
Ergotamine—Vomiting—Triamcinolone—hematologic cancer	6.9e-05	0.000594	CcSEcCtD
Ergotamine—Vertigo—Doxorubicin—hematologic cancer	6.83e-05	0.000588	CcSEcCtD
Ergotamine—Hypertension—Doxorubicin—hematologic cancer	6.56e-05	0.000565	CcSEcCtD
Ergotamine—Tachycardia—Epirubicin—hematologic cancer	6.54e-05	0.000563	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	6.53e-05	0.000562	CcSEcCtD
Ergotamine—Myalgia—Doxorubicin—hematologic cancer	6.47e-05	0.000557	CcSEcCtD
Ergotamine—Nausea—Triamcinolone—hematologic cancer	6.45e-05	0.000555	CcSEcCtD
Ergotamine—Paraesthesia—Methotrexate—hematologic cancer	6.43e-05	0.000554	CcSEcCtD
Ergotamine—Vomiting—Betamethasone—hematologic cancer	6.26e-05	0.000539	CcSEcCtD
Ergotamine—Vomiting—Dexamethasone—hematologic cancer	6.26e-05	0.000539	CcSEcCtD
Ergotamine—Asthenia—Prednisone—hematologic cancer	6.15e-05	0.00053	CcSEcCtD
Ergotamine—Pain—Methotrexate—hematologic cancer	6.13e-05	0.000527	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	6.11e-05	0.000526	CcSEcCtD
Ergotamine—Pruritus—Prednisone—hematologic cancer	6.07e-05	0.000522	CcSEcCtD
Ergotamine—Tachycardia—Doxorubicin—hematologic cancer	6.06e-05	0.000521	CcSEcCtD
Ergotamine—Paraesthesia—Epirubicin—hematologic cancer	6.02e-05	0.000518	CcSEcCtD
Ergotamine—Nausea—Dexamethasone—hematologic cancer	5.85e-05	0.000503	CcSEcCtD
Ergotamine—Nausea—Betamethasone—hematologic cancer	5.85e-05	0.000503	CcSEcCtD
Ergotamine—Pain—Epirubicin—hematologic cancer	5.73e-05	0.000494	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	5.65e-05	0.000487	CcSEcCtD
Ergotamine—Paraesthesia—Doxorubicin—hematologic cancer	5.57e-05	0.00048	CcSEcCtD
Ergotamine—Vomiting—Prednisone—hematologic cancer	5.45e-05	0.000469	CcSEcCtD
Ergotamine—Pain—Doxorubicin—hematologic cancer	5.31e-05	0.000457	CcSEcCtD
Ergotamine—Asthenia—Methotrexate—hematologic cancer	5.14e-05	0.000443	CcSEcCtD
Ergotamine—Nausea—Prednisone—hematologic cancer	5.09e-05	0.000438	CcSEcCtD
Ergotamine—Pruritus—Methotrexate—hematologic cancer	5.07e-05	0.000436	CcSEcCtD
Ergotamine—Dihydroergotamine—ABCB1—hematologic cancer	4.96e-05	0.415	CrCbGaD
Ergotamine—Asthenia—Epirubicin—hematologic cancer	4.81e-05	0.000414	CcSEcCtD
Ergotamine—Pruritus—Epirubicin—hematologic cancer	4.74e-05	0.000408	CcSEcCtD
Ergotamine—Vomiting—Methotrexate—hematologic cancer	4.56e-05	0.000392	CcSEcCtD
Ergotamine—Ergonovine—ABCB1—hematologic cancer	4.53e-05	0.379	CrCbGaD
Ergotamine—Asthenia—Doxorubicin—hematologic cancer	4.45e-05	0.000383	CcSEcCtD
Ergotamine—Pruritus—Doxorubicin—hematologic cancer	4.39e-05	0.000378	CcSEcCtD
Ergotamine—Vomiting—Epirubicin—hematologic cancer	4.26e-05	0.000367	CcSEcCtD
Ergotamine—Nausea—Methotrexate—hematologic cancer	4.26e-05	0.000366	CcSEcCtD
Ergotamine—Nausea—Epirubicin—hematologic cancer	3.98e-05	0.000343	CcSEcCtD
Ergotamine—Vomiting—Doxorubicin—hematologic cancer	3.94e-05	0.00034	CcSEcCtD
Ergotamine—Nausea—Doxorubicin—hematologic cancer	3.69e-05	0.000317	CcSEcCtD
Ergotamine—Bromocriptine—ABCB1—hematologic cancer	2.46e-05	0.206	CrCbGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	1.77e-06	2.25e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MTOR—hematologic cancer	1.77e-06	2.25e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.77e-06	2.25e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	1.77e-06	2.25e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	1.76e-06	2.25e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PTEN—hematologic cancer	1.76e-06	2.24e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EP300—hematologic cancer	1.75e-06	2.23e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	1.74e-06	2.23e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	1.74e-06	2.22e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—JUN—hematologic cancer	1.74e-06	2.22e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.73e-06	2.21e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK3—hematologic cancer	1.73e-06	2.21e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	1.73e-06	2.21e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	1.73e-06	2.21e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	1.73e-06	2.21e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	1.72e-06	2.2e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	1.72e-06	2.19e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	1.71e-06	2.19e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HRAS—hematologic cancer	1.71e-06	2.19e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—SRC—hematologic cancer	1.7e-06	2.17e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	1.69e-06	2.16e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	1.69e-06	2.15e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	1.69e-06	2.15e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EP300—hematologic cancer	1.69e-06	2.15e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MYC—hematologic cancer	1.68e-06	2.15e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	1.68e-06	2.15e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	1.68e-06	2.15e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	1.68e-06	2.15e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EP300—hematologic cancer	1.68e-06	2.14e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—KRAS—hematologic cancer	1.67e-06	2.14e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	1.67e-06	2.13e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	1.67e-06	2.13e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTEN—hematologic cancer	1.66e-06	2.12e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.66e-06	2.12e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	1.66e-06	2.12e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	1.65e-06	2.11e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	1.65e-06	2.11e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	1.65e-06	2.11e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CASP3—hematologic cancer	1.65e-06	2.11e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL2—hematologic cancer	1.65e-06	2.1e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.65e-06	2.1e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	1.65e-06	2.1e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	1.64e-06	2.1e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—hematologic cancer	1.64e-06	2.09e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	1.64e-06	2.09e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—SRC—hematologic cancer	1.64e-06	2.09e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	1.64e-06	2.09e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	1.64e-06	2.09e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	1.63e-06	2.08e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SRC—hematologic cancer	1.63e-06	2.08e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CASP3—hematologic cancer	1.62e-06	2.07e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	1.62e-06	2.07e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL2—hematologic cancer	1.62e-06	2.07e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—hematologic cancer	1.62e-06	2.06e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—hematologic cancer	1.61e-06	2.06e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CREBBP—hematologic cancer	1.61e-06	2.05e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCND1—hematologic cancer	1.61e-06	2.05e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	1.61e-06	2.05e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	1.61e-06	2.05e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	1.61e-06	2.05e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EP300—hematologic cancer	1.6e-06	2.05e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—JUN—hematologic cancer	1.6e-06	2.05e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	1.6e-06	2.04e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	1.59e-06	2.03e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL2—hematologic cancer	1.59e-06	2.03e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	1.59e-06	2.03e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—EP300—hematologic cancer	1.58e-06	2.02e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—hematologic cancer	1.58e-06	2.02e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCND1—hematologic cancer	1.58e-06	2.02e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	1.58e-06	2.02e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—STAT3—hematologic cancer	1.58e-06	2.02e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—JUN—hematologic cancer	1.58e-06	2.01e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NRAS—hematologic cancer	1.58e-06	2.01e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—STAT3—hematologic cancer	1.57e-06	2.01e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NRAS—hematologic cancer	1.57e-06	2e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.57e-06	2e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	1.56e-06	2e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SRC—hematologic cancer	1.56e-06	1.99e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	1.56e-06	1.99e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	1.55e-06	1.98e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PTEN—hematologic cancer	1.55e-06	1.98e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	1.55e-06	1.98e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HRAS—hematologic cancer	1.55e-06	1.97e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	1.55e-06	1.97e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	1.54e-06	1.96e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	1.53e-06	1.96e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	1.53e-06	1.95e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	1.53e-06	1.95e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.52e-06	1.95e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	1.52e-06	1.94e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	1.52e-06	1.94e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK8—hematologic cancer	1.52e-06	1.94e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	1.52e-06	1.94e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HRAS—hematologic cancer	1.51e-06	1.93e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—AKT1—hematologic cancer	1.51e-06	1.93e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	1.51e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	1.51e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ALB—hematologic cancer	1.51e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	1.5e-06	1.92e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	1.5e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	1.5e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	1.5e-06	1.91e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	1.49e-06	1.91e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	1.49e-06	1.91e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.49e-06	1.9e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	1.49e-06	1.9e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—hematologic cancer	1.49e-06	1.9e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.48e-06	1.89e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—hematologic cancer	1.48e-06	1.89e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EP300—hematologic cancer	1.48e-06	1.89e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.48e-06	1.89e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.48e-06	1.88e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.47e-06	1.87e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.47e-06	1.87e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.46e-06	1.87e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	1.46e-06	1.87e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MYC—hematologic cancer	1.46e-06	1.86e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	1.46e-06	1.86e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	1.46e-06	1.86e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EP300—hematologic cancer	1.46e-06	1.86e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.45e-06	1.85e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—hematologic cancer	1.45e-06	1.85e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.44e-06	1.84e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.44e-06	1.84e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.44e-06	1.84e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.44e-06	1.84e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SRC—hematologic cancer	1.44e-06	1.84e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	1.44e-06	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.44e-06	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	1.43e-06	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	1.43e-06	1.82e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HRAS—hematologic cancer	1.42e-06	1.82e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SRC—hematologic cancer	1.42e-06	1.81e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	1.41e-06	1.79e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—hematologic cancer	1.4e-06	1.79e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	1.4e-06	1.78e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	1.4e-06	1.78e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.39e-06	1.78e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.39e-06	1.77e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—STAT3—hematologic cancer	1.39e-06	1.77e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	1.39e-06	1.77e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.38e-06	1.77e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NRAS—hematologic cancer	1.38e-06	1.77e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—hematologic cancer	1.38e-06	1.77e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	1.38e-06	1.76e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	1.37e-06	1.74e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—AKT1—hematologic cancer	1.37e-06	1.74e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	1.36e-06	1.74e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—hematologic cancer	1.36e-06	1.74e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.36e-06	1.73e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.36e-06	1.73e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.35e-06	1.73e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	1.35e-06	1.72e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	1.35e-06	1.72e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—AKT1—hematologic cancer	1.34e-06	1.71e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	1.34e-06	1.71e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	1.33e-06	1.7e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.33e-06	1.7e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK3—hematologic cancer	1.33e-06	1.69e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.32e-06	1.69e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	1.32e-06	1.69e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	1.3e-06	1.66e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	1.29e-06	1.65e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.29e-06	1.65e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MYC—hematologic cancer	1.29e-06	1.65e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.29e-06	1.64e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TGFB1—hematologic cancer	1.29e-06	1.64e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.28e-06	1.64e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	1.28e-06	1.63e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.27e-06	1.62e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.27e-06	1.62e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—hematologic cancer	1.27e-06	1.62e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.27e-06	1.62e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—AKT1—hematologic cancer	1.26e-06	1.6e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.25e-06	1.6e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	1.25e-06	1.59e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.25e-06	1.59e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	1.24e-06	1.59e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.24e-06	1.59e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	1.24e-06	1.58e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	1.24e-06	1.58e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.24e-06	1.58e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.22e-06	1.55e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.21e-06	1.54e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ALB—hematologic cancer	1.2e-06	1.53e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—hematologic cancer	1.2e-06	1.53e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	1.19e-06	1.52e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—KRAS—hematologic cancer	1.19e-06	1.52e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	1.19e-06	1.52e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	1.19e-06	1.51e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.17e-06	1.5e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	1.17e-06	1.5e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	1.17e-06	1.49e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.15e-06	1.47e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.15e-06	1.47e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.15e-06	1.47e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.15e-06	1.47e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTEN—hematologic cancer	1.15e-06	1.47e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	1.15e-06	1.47e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	1.15e-06	1.46e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	1.15e-06	1.46e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	1.14e-06	1.46e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.1e-06	1.41e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	1.1e-06	1.4e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.1e-06	1.4e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—EP300—hematologic cancer	1.1e-06	1.4e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.09e-06	1.4e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.08e-06	1.37e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.07e-06	1.36e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.07e-06	1.36e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.06e-06	1.35e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—hematologic cancer	1.06e-06	1.35e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	1.05e-06	1.35e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	1.05e-06	1.35e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	1.05e-06	1.34e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.04e-06	1.33e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	1.02e-06	1.3e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—AKT1—hematologic cancer	1.02e-06	1.3e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.01e-06	1.29e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.01e-06	1.29e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	9.96e-07	1.27e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.91e-07	1.26e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	9.8e-07	1.25e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	9.76e-07	1.25e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	9.7e-07	1.24e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—hematologic cancer	9.69e-07	1.24e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—AKT1—hematologic cancer	9.57e-07	1.22e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—hematologic cancer	9.54e-07	1.22e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	9.48e-07	1.21e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	9.39e-07	1.2e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	9.34e-07	1.19e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALB—hematologic cancer	9.27e-07	1.18e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTEN—hematologic cancer	9.17e-07	1.17e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	9.06e-07	1.16e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—AKT1—hematologic cancer	8.94e-07	1.14e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.87e-07	1.13e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	8.8e-07	1.12e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—EP300—hematologic cancer	8.74e-07	1.12e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	8.68e-07	1.11e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	8.61e-07	1.1e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	8.19e-07	1.05e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CA—hematologic cancer	8.1e-07	1.03e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	8e-07	1.02e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTEN—hematologic cancer	7.08e-07	9.03e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—EP300—hematologic cancer	6.75e-07	8.61e-06	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AKT1—hematologic cancer	6.62e-07	8.45e-06	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	6.47e-07	8.25e-06	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AKT1—hematologic cancer	5.28e-07	6.74e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.99e-07	6.37e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AKT1—hematologic cancer	4.08e-07	5.2e-06	CbGpPWpGaD
